

PRESS RELEASE

CamDiab Launches iOS Companion Feature for CamAPS FX

Cambridge, UK – 23 September 2025 – CamDiab Ltd, the digital health and medical device company behind the CamAPS FX app, today announced the launch of its **iOS Companion feature**. Previously available only on Android, this expansion to iOS ensures broader access to remote monitoring, bringing additional flexibility and peace of mind to families and caregivers supporting people living with type 1 diabetes.

As of the 23rd September 2025, an iOS CamAPS FX app update, including this new feature, will be rolled out. iPhone users have been notified of the update's availability via an in-app message.

The Companion feature enables designated caregivers to view real-time glucose levels, insulin delivery, and alerts. This allows them to provide timely support, giving the person living with type 1 diabetes more freedom and confidence in managing their demanding condition.

With the launch of the iOS Companion feature, iPhone users can now also be invited as companions from the user's CamAPS FX app. Companions can use an iPhone or Android smartphone and receive data from either Android or iPhone CamAPS FX app users. Both the user and companion will need to be on the latest app version to share data.

Professor Roman Hovorka, co-founder of CamDiab and Professor of Metabolic Technology at the University of Cambridge, commented:

"We are delighted to bring the Companion feature to iPhone users. This enhancement will further support parents and other caregivers in remotely monitoring loved ones living with type 1 diabetes, offering reassurance and improved safety while easing the daily burden of diabetes management."

About CamDiab:

CamDiab Ltd is a digital health and medical device company founded in 2019 as a spin-out from the University of Cambridge. The company is dedicated to the design, development, and commercialization of its world-leading, interoperable, and clinically proven **CamAPS FX app**, an adaptive, hybrid closed-loop system for people living with type 1 diabetes.

For more information, please visit: www.camdiab.com

ENDS

Notes to editors: For further information, please email candice.ward@camdiab.com.

